Corline Biomedical AB OMXSTO:CLBIO:
SIGNS 10-YEAR AGREEMENT WITH KARDIUM
Corline Biomedical Signs 10-Year Agreement With Kardium
Story so far
Earlier from Corline Biomedical
- CLBIO: Growth depends on Kardium's US launch, with cost cuts improving results despite lower sales
- CLBIO: Corline's Q1 2025 loss widens, but US market entry and strong clinical data drive optimism
- CLBIO: 2024 saw heavy losses and restructuring, but Corline targets US growth with CHSTM-coated Globe®
- CLBIO: Sharply reduced costs and strategic focus position Corline for growth and profitability by 2025
- CLBIO: Revenue down, losses widened, but US launch and new projects drive future potential
Later from Corline Biomedical
- CLBIO: Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth
- Corline Flags Share Issue Raising About SEK 9.24 Mln
- CLBIO: FDA approval, US launch, and a major 10-year deal drove a pivotal commercial breakthrough
- Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence
- Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln
Follow Corline Biomedical into a list and get an email when it puts out news.
Follow Corline Biomedical